Somatostatin Analogues in Bronchial Neuroendocrine Tumors: Symptom Control and Anti-Proliferative Role Abstract #1146

Introduction: There is no established fist-line medical treatment for advanced bronchial NETs.
Aim(s): To assess the symptom-control & antiproliferative efficacy (time-to-first-radiological-progression) of somatostatin-analogues (SA).
Materials and methods: Patients with histologically confirmed bronchial-NETs (typical/atypical-carcinoids), with & without primary resection, and with tumour-uptake in Octreoscan &/or Ga-68-Octreotate PET were retrospectively reviewed. None had received any systemic treatment prior to SA-commencement. A symptom-score & radiological assessment by RECIST were utilized.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr Efthimia Karra
Keywords: Bronchial NET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1745 High Rate of Second Neoplasms in Patients with a Bronchial Neuroendocrine Tumor
Introduction: Bronchial neuroendocrine tumors (NETs) are classified as typical carcinoids (TC), atypical carcinoids (AC), large cell neuroendocrine carcinomas (LCNEC), or small cell lung carcinomas (SCLC)
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Federica Alessandra Cavalcoli
#1242 Epidemiological Characteristics from a Single Centre Database. Cohort of 1301 Neuroendocrine Tumor Patients: Is There an Association Between Age and Grade of NET?
Introduction: There is limited data related to epidemiology of NETs and patient survival. For many cancers younger age of diagnosis can be associated with worse survival.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Mehmet Yalchin
Keywords: Survival
#250 Circulating Tumor Cells (CTCs) Correlate with Overall Survival in Neuroendocrine Tumors (NETs)
Introduction: Using the CellSearchTM system, circulating tumor cells (CTCs) can be reproducibly enumerated. We have previously shown that CTCs are detectable in NETs and associated with progressive disease.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#1238 Use of Everolimus in a Patient with Metastatic Bronchial Carcinoid Receiving Hemodialysis.
Introduction: Renal impairment may alter the normal pharmacokinetic and pharmacodynamic behavior of chemotherapy drugs, thus increasing the risk of side effects. Everolimus was reported to have anti-tumor activity in bronchial neuroendocrine tumors (NET). Safety and toxicity profile of everolimus has been provided in hemodialyzed patients with renal cell carcinoma. Only a report describes the effect of everolimus in a patient with metastatic ileac carcinoid in hemodialysis.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: MD Maria Pia Brizzi
#726 Expression and Phosphorilation of mTOR Pathway and Antitumor Activity of mTOR Inhibitors in Neuroendocrine Tumors
Introduction: The mammalian target of rapamycin (mTOR) is a protein kinase involved in the control of cancer cell metabolism, growth and proliferation. The mTOR pathway has attracted broad scientific and clinical interest, particularly in light of the ongoing clinical cancer trials with mTOR inhibitors in pts with neuroendocrine tumors (NETs). To identify the best candidates for treatment with mTOR inhibitors is challenging.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Concetta Sciammarella